Rotundine b

CAS No. 483-14-7

Rotundine b( L-Tetrahydropalmatine | (-)-Tetrahydropalmatine | Caseanine | Gindarine )

Catalog No. M19458 CAS No. 483-14-7

Rotundine (L-tetrahydropalmatine L-THP) is a selective dopamine D1 receptor antagonist with IC50 of 166 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 47 Get Quote
100MG 68 Get Quote
500MG 165 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Rotundine b
  • Note
    Research use only, not for human use.
  • Brief Description
    Rotundine (L-tetrahydropalmatine L-THP) is a selective dopamine D1 receptor antagonist with IC50 of 166 nM.
  • Description
    Rotundine (L-tetrahydropalmatine L-THP) is a selective dopamine D1 receptor antagonist with IC50 of 166 nM.(In Vivo):It is reported that Rotundine (l-THP) possesses a blocking effect on dopamine D1 and D2 receptors and can inhibit physical dependence in morphine dependent mice and significantly reduce the development of the conditional place preference induced by morphine in mice. On day 1 and 7, there is no difference in locomotor counts between the Rotundine groups (6.25, 12.5, and 18.75 mg/kg) and saline group [F(3, 37)=1.360, P>0.05, F(3, 37)=0.348, P>0.05, respectively]. Locomotor counts are greatly increased in the oxycodone group compare with the saline group. Rotundine at doses of 6.25, 12.5, and 18.75 mg/kg antagonizes hyperactivity induced by oxycodone [F(4, 60)=15.76, P<0.01]. Rotundine (6.25, 12.5 mg/kg) does not affect the magnitude of sensitization, but there is a marked difference between oxycodone+oxycodone group and Rotundine (18.75 mg/kg)+oxycodone+oxycodone group, indicating that Rotundine (18.75 mg/kg) greatly inhibits the development of oxycodone sensitization [F(4, 62)=8.766, P<0.01].
  • In Vitro
    ——
  • In Vivo
    It is reported that Rotundine (l-THP) possesses a blocking effect on dopamine D1 and D2 receptors and can inhibit physical dependence in morphine dependent mice and significantly reduce the development of the conditional place preference induced by morphine in mice. On day 1 and 7, there is no difference in locomotor counts between the Rotundine groups (6.25, 12.5, and 18.75 mg/kg) and saline group [F(3, 37)=1.360, P>0.05, F(3, 37)=0.348, P>0.05, respectively]. Locomotor counts are greatly increased in the oxycodone group compare with the saline group. Rotundine at doses of 6.25, 12.5, and 18.75 mg/kg antagonizes hyperactivity induced by oxycodone [F(4, 60)=15.76, P<0.01]. Rotundine (6.25, 12.5 mg/kg) does not affect the magnitude of sensitization, but there is a marked difference between oxycodone+oxycodone group and Rotundine (18.75 mg/kg)+oxycodone+oxycodone group, indicating that Rotundine (18.75 mg/kg) greatly inhibits the development of oxycodone sensitization [F(4, 62)=8.766, P<0.01].
  • Synonyms
    L-Tetrahydropalmatine | (-)-Tetrahydropalmatine | Caseanine | Gindarine
  • Pathway
    GPCR/G Protein
  • Target
    Dopamine Receptor
  • Recptor
    D1 receptor 5-HT1A D2 receptor D3 receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    483-14-7
  • Formula Weight
    355.43
  • Molecular Formula
    C21H25NO4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:8 mg/mL (22.5 mM);Ethanol:<1 mg/mL;Water:<1 mg/mL
  • SMILES
    [H][C@@]12CC3=CC=C(OC)C(OC)=C3CN1CCC1=C2C=C(OC)C(OC)=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Wang JB et al. Future Med Chem 2012 4(2) 177-186.
molnova catalog
related products
  • CCT241736

    CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant mutants including FLT3-ITD and FLT3.

  • Tedatioxetine

    Tedatioxetine (Lu AA24530) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) with antidepressant properties.Tedatioxetine acts as a CYP2D6 substrate.

  • NMI 8739

    NMI 8739 is an agonist of D2 autoreceptor. NMI 8739 reduces NO production and elicits concentration-dependent suppression of CCL-20, MCP-1 and IL-6 release.